Lupus Sci. Med. 2023;10(2):e001074 DOI 10.1136/lupus-2023-001074
In this study, telitacicept add-on therapy demonstrated desirable real-world safety and efficacy profiles for the management of SLE, LN, and patients with haematological abnormalities. Jin et al conducted a retrospective analysis of SLE patients who had received a minimum of 24 weeks of telitacicept therapy, across three separate centres in China. The safety and efficacy results are promising and reflect the existing clinical trial data, and factors associated with a limited response were identified.